Constantin Meyer - STADA Arzneimittel Insider

STADA Arzneimittel Aktiengesellschaft -- USA Stock  

USD 93.75  0.00  0.00%

Member of the Supervisory Board

Mr. Constantin Meyer was Member of the Supervisory Board of STADA Arzneimittel AG from 2003 to August 26 2016. Since 1974 He was Chairman of the Examination Board for Pharmaceutical Technicians and Assistants of the Lower Saxon Chamber of Pharmacists. He has previously worked as a control manager and pharmaceutical advisor. From 1986 to 1992 he was responsible for the growth of MEDICA MEYER until its merger with Phabil Bielefeld. In 1986 he became Chairman of the Advisory Board of STADA Arzneimittel AG. He studied pharmacy at LudwigsUniversitaet zu Freiburg in Breisgau Germany and gained his pharmaceutical licence in 1971.
Age: 72  Executive Since 2003      
49 6101 6030  http://www.stada.de

Management Efficiency

The company has return on total asset (ROA) of 5.26 % which means that it generated profit of $5.26 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 9.8 % meaning that it generated $9.8 on every $100 dollars invested by stockholders.
The company has accumulated 1.69 B in total debt with debt to equity ratio (D/E) of 134.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. STADA Arzneimittel Aktiengesellschaft has Current Ratio of 0.67 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. STADA Arzneimittel Aktiengesellschaft (STDAF) is traded on OTC Market in USA. It is located in Bad Vilbel, and employs 10,872 people.

Did you try this?

Run Equity Analysis Now
   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Hide  View All  NextLaunch Equity Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add STADA Arzneimittel Aktiengesellschaft to your portfolio

Top Management

STADA Arzneimittel A Leadership Team
Carl Oetker, Executive
JanNicolas Garbe, Executive
Dieter Koch, Executive
Eckhard Brueggemann, Executive, Ph.D
Mark Keatley, CFO
Ralph Grobecker, Managing Director, Ph.D
Martin Abend, Chairman, Ph.D
Matthias Wiedenfels, Executive, Ph.D
Arnold Hertzsch, Executive, Ph.D
Halil Duru, Executive
Tina Mueller, Executive
Engelbert Willink, Chairman
Barthold Piening, Executive, Ph.D
Helmut Kraft, CFO
Ute Pantke, Executive, Ph.D
Hartmut Retzlaff, Chairman
Bernhard Duettmann, CFO
Claudio Albrecht, Chairman, Ph.D
Michael Siefke, Executive
Leslie Iltgen, President
Eric Cornut, Executive
Jens Steegers, Executive
Birgit Kudlek, Executive, Ph.D
Guenter Au, Chairman, Ph.D
Constantin Meyer, Executive
Rolf Hoffmann, Executive, MBA
Markus Metzger, Director
Benjamin Kunstler, Executive
Gunnar Riemann, Executive, Ph.D
Bruno Schick, Executive

Stock Performance

STADA Arzneimittel Performance Indicators